AstraZeneca — Investor Presentation

5 slides from AstraZeneca's investor presentation

Slide 1: Concluding Remarks
Concluding Remarks Tom McKillop Chief Executive Officer The product portfolio h Redesigned R&D h Reprioritised portfolio h 57 nce’s: 159 projects h 11 nce’s: 20 projects in priority 1 h Clear targets for each TA h All major projects on track 1
Slide 2: AstraZeneca today has a competitive product portfolio
AstraZeneca today has a competitive product portfolio Total 1998 sales, $ million Top selling drugs Rank in therapeutic class, 1998 GI 3,211 Losec® (3165) 1 Zestril® (1126) 2 CV 2,936 Tenormin® (502) 1 Seloken® (450) 2 Zoladex® (626) 2 Oncology 1,538 Nolvadex® (526) 1 Respiratory 1,256 Pulmicort® (6
Slide 3: Top brands capturing more value
Top brands capturing more value 1994–98 1998–2002(E) 75% 42% 34% 24% Market Growth in Market Growth in growth average sales growth average sales of top 20 of top 20 Source: IMS; Evaluate PLC Trend towards more megabrands Number of products with sales > USD 1 billion ~50 23 13 1994 1998 2002E Share o
Slide 4: Megabrands: Our product priorities over time
“Megabrands” Nexium™ Seroquel® Superstatin Atacand® Thrombin Inhibitor 10+ others Arimidex® Viozan™ (longer term) Casodex® Iressa™ Our product priorities over time 2000 2001 2002 “Megabrands”/ 1 Nexium™/Losec® 1 Nexium™/Losec® 1 ZD4522 launches to support 2 Atacand® 2 Atacand® 2 Viozan™ 3 Respirator
Slide 5: 5
5